

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

EIGER BIOPHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

28249U105

(CUSIP Number)

December 31, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☐ Rule 13d-1(c)
- ☒ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 28249U105

13G

1. Names of Reporting Persons
HBM Healthcare Investments (Cayman) Ltd.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

- (a) ☐
- (b) ☐

3. SEC Use Only

4. Citizenship or Place of Organization
Cayman Islands, British West Indies

5. Sole Voting Power
580,000 ⁽¹⁾

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:

6. Shared Voting Power
0

7. Sole Dispositive Power
580,000 ⁽¹⁾

8. Shared Dispositive Power
0

9. Aggregate Amount Beneficially Owned by Each Reporting Person

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

11. Percent of Class Represented by Amount in Row 9
5.52%⁽²⁾

12. Type of Reporting Person (See Instructions)
CO

(1) Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. The board of directors of HBM Healthcare Investments (Cayman) Ltd. consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares.

(2) This percentage is calculated based upon 10,516,406 shares of the Issuer's Common Stock outstanding as of November 3, 2017, as set forth in Issuer's Form 10-Q dated November 9, 2017, filed with the Securities and Exchange Commission on November 9, 2017.

Item 1(a). Name of Issuer:
Eiger Pharmaceuticals, Inc..

Item 1(b). Address of Issuer's Principal Executive Offices:
350 Cambridge Drive
Suite 350
Palo Alto, CA 94306

Item 2(a). Name of Person Filing:
HBM Healthcare Investments (Cayman) Ltd.

Item 2(b). Address of Principal Business Office or, if none, Residence:
Governors Square
Suite #4-212-2
23 Lime Tree Bay Avenue
West Bay
Grand Cayman, Cayman Islands

Item 2(c). Citizenship:
Cayman Islands, British West Indies

Item 2(d). Title of Class of Securities:
Common Stock

Item 2(e). CUSIP Number:
28249U105

Item 3. **If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:**

Not applicable

Item 4. Ownership

(a) Amount beneficially owned:
580,000⁽¹⁾

(b) Percent of class:
5.52%⁽²⁾

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote
580,000⁽¹⁾

(ii) Shared power to vote or to direct the vote:
0

(iii) Sole power to dispose or to direct the disposition of:

580,000⁽¹⁾

- (iv) Shared power to dispose or to direct the disposition of:
0

3

Item 5. Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o.

Item 6. Ownership of More than 5 Percent on Behalf of Another Person

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of a Group

Not applicable

- (1) Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. The board of directors of HBM Healthcare Investments (Cayman) Ltd. consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares.
- (2) This percentage is calculated based upon 10,516,406 shares of the Issuer's Common Stock outstanding as of November 3, 2017, as set forth in Issuer's Form 10-Q dated November 9, 2017, filed with the Securities and Exchange Commission on November 9, 2017.

4

Item 10. Certification

Not applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2018

HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD.

By: /s/ Jean-Marc LeSieur
Jean-Marc LeSieur, Managing Director

ATTENTION:

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)

5